HIV-1 infection
Infectious disease · 2007–2023
23decisions
16medicines
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lenacapavir Treatment of adults with highly multidrug-resistant HIV-1 infection in combination with optimised background regimen, for patients who have no more than 2… | Nov 2023 | Recommended with restriction | input received National Association · HIV Australia |
| cabotegravir and rilpivirine Treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL). Cabotegravir tablets are for oral lead-in prior to… | Mar 2021 | Not recommended | input received National Association |
| cabotegravir and rilpivirine Treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) and have no known or… | Nov 2021 | Recommended with restriction | unclear |
| dolutegravir with lamivudine Extension of listing for DTG/3TC fixed-dose combination to include treatment-experienced (switch) patients with HIV-1 infection who are virologically… | Jul 2020 | Recommended with restriction | none received |
| dolutegravir with lamivudine Treatment of HIV-1 infection in adult and adolescent patients aged 12 years or older. The submission sought listing for both treatment-naïve and… | Jul 2019 | Deferred | unclear |
| dolutegravir with lamivudine Treatment of HIV-1 infection in adult and adolescent patients aged 12 years or older weighing 40 kg or more. The submission proposed listing for both… | Jul 2019 | Deferred | unclear |
| tenofovir disoproxil fumarate with emtricitabine and efavirenz; tenofovir disoproxil fumarate with emtricitabine and rilpivirine; tenofovir disoproxil fumarate with emtricitabine, elvitegravir and cobicistat Treatment of HIV-1 infection in adults. These are fixed-dose combination products containing tenofovir with emtricitabine and various third agents (efavirenz,… | Mar 2019 | Deferred | no section in document |
| bictegravir + emtricitabine + tenofovir alafenamide Treatment of human immunodeficiency virus (HIV-1) infection in treatment-naïve and virologically suppressed patients. | Mar 2018 | Recommended with restriction | none received |
| raltegravir Treatment of HIV-1 infection in combination with other antiretroviral agents, in treatment-naïve patients, treatment-experienced patients, and patients… | Jul 2017 | Deferred | none received |
| tenofovir alafenamide / emtricitabine Treatment of HIV-1 infection in antiretroviral treatment-naïve and treatment-experienced patients, in combination with other antiretroviral agents. | Jul 2016 | Deferred | none received |
| darunavir + cobicistat Treatment of HIV-1 infection in combination with other antiretroviral agents in antiretroviral treatment-naïve patients and in treatment-experienced patients… | Mar 2016 | Recommended with restriction | none received |
| elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide Treatment of HIV-1 infection in treatment-naïve patients and treatment-experienced patients with a clinical indication to switch components of therapy. | Nov 2015 | Recommended with restriction | none received |
| atazanavir/cobicistat Treatment of HIV-1 infection in combination with other antiretroviral agents in treatment-naïve and treatment-experienced patients. | Nov 2015 | Recommended with restriction | none received |
| elvitegravir Continuing treatment of HIV-1 infection in antiretroviral treatment-experienced adults and adolescents in combination with a ritonavir-boosted protease… | Mar 2013 | Not recommended | no section in document |
| maraviroc For the targeted treatment of all patients with CCR5-tropic HIV-1 infection, in combination with other antiretroviral agents. For initial treatment and… | Nov 2012 | Deferred | no section in document |
| maraviroc First-line treatment of adult patients with CCR5-tropic HIV-1 infection in combination with other antiretroviral agents; also continuing treatment of HIV-1… | Nov 2012 | Deferred | no section in document |
| raltegravir potassium Treatment of HIV-1 infection in treatment-naïve patients in combination with other antiretroviral agents, for patients with evidence of HIV replication (viral… | Mar 2010 | Recommended with restriction | no section in document |
| raltegravir potassium Treatment of human immunodeficiency virus (HIV-1) infection in treatment naïve patients in combination with other antiretroviral agents, with evidence of HIV… | Mar 2010 | Recommended with restriction | no section in document |
| etravirine Treatment of HIV-1 infection in combination with other antiretroviral agents in antiretroviral treatment-experienced adults with evidence of viral replication… | Mar 2009 | Recommended with restriction | no section in document |
| darunavir Treatment of HIV-1 infection in combination with other antiretroviral agents in antiretroviral-experienced patients who have failed previous treatment with, or… | Nov 2009 | Recommended with restriction | no section in document |
| maraviroc Treatment in combination with other antiretrovirals of antiretroviral experienced adult patients infected with only CCR5-tropic HIV-1 with evidence of HIV… | Nov 2009 | Recommended with restriction | no section in document |
| maraviroc Treatment of antiretroviral-experienced adult patients infected with CCR5-tropic HIV-1, in combination with other antiretrovirals. | Nov 2008 | Recommended | no section in document |
| darunavir ethanolate Treatment of HIV-1 infection in antiretroviral treatment-experienced patients with evidence of viral replication and/or CD4 cell counts <500 cells/mm³, who… | Jul 2007 | Recommended with restriction | no section in document |
Who spoke
National Association · HIV Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 13 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.